GlassScriptPhysician profile
Gina Grace Mentzer
NPI 1316168628
$26,805.54
in general payments reported to CMS, 2019-2025
45 companies · $980 in 2025
The $980 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,685 · 2021: $780 · 2022: $866 · 2023: $670 · 2024: $1,284 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,845.03 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15,140.92 | 2019-2025 | |
| Boston Scientific Corporation | $7,292.48 | 2019-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $419.86 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $398.39 | 2021-2025 | Opsumit, Uptravi |
| Pfizer INC. | $334.33 | 2019-2025 | |
| Amgen INC. | $332.92 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.12 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $258.22 | 2019-2024 | Xarelto |
| Scpharmaceuticals INC. | $226.01 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $206.08 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $168.70 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $140.32 | 2019-2024 | Wainua, Farxiga, Brilinta |
| Novo Nordisk INC | $125.21 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.20 | 2019-2025 | Lifevest |
| Itamar Medical INC | $103.65 | 2022-2023 | Watchpatone |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $97.31 | 2022-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $90.13 | 2019-2025 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $87.14 | 2021-2024 | Onpattro |
| Bridgebio Pharma, INC. | $80.93 | 2025 | Attruby |
| Amarin Pharma, INC. | $77.85 | 2019-2021 | |
| Abbott Laboratories | $74.92 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Esperion Therapeutics, INC. | $61.01 | 2020-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $58.90 | 2022-2023 | Optimizer |
| Medtronic Vascular, INC. | $57.28 | 2019 | |
| Heartflow, INC. | $54.70 | 2025 | |
| Edwards Lifesciences Corporation | $54.02 | 2023-2024 | |
| Lundbeck LLC | $46.92 | 2020-2021 | |
| Medtronic, INC. | $37.98 | 2024 | Complete Se Vascular |
| Kiniksa Pharmaceuticals International, Plc | $35.17 | 2024 | Arcalyst |
| Baxter Healthcare | $31.79 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Glaxosmithkline, LLC. | $28.72 | 2025 | Arexvy, Shingrix |
| Cardiva Medical, INC. | $27.85 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Gilead Sciences, INC. | $26.56 | 2019 | |
| Teleflex LLC | $23.08 | 2023 | Guideliner |
| Inspire Medical Systems, INC. | $21.12 | 2025 | Inspire |
| Amryt Pharma Holdings LTD | $18.14 | 2021 | |
| United Therapeutics Corporation | $17.83 | 2023 | Tyvaso |
| Philips North America LLC | $17.42 | 2024 | (5044) Mcot |
| Daiichi Sankyo INC. | $16.31 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $15.38 | 2025 | |
| Arbor Pharmaceuticals, INC. | $14.69 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.34 | 2024 | |
| Ge Healthcare | $13.28 | 2021 | |
| Genentech USA, INC. | $11.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Mentzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.